Does colistin (polymyxin E) and fluconazole cause torsades de pointes?

Fluconazole Can Cause Torsades de Pointes; Colistin Can Rarely Cause It Through Electrolyte Disturbances

Fluconazole is a documented cause of QT prolongation and torsades de pointes (TdP), while colistin can indirectly trigger TdP through severe electrolyte derangements, not through direct QT prolongation. These mechanisms differ fundamentally and require distinct monitoring approaches.

Fluconazole and Torsades de Pointes

Fluconazole directly prolongs the QT interval by inhibiting the Rectifier Potassium Channel current (IKr) 1. The FDA drug label explicitly states that post-marketing surveillance has documented rare cases of QT prolongation and torsades de pointes in patients taking fluconazole 1. Most cases involved seriously ill patients with multiple risk factors including structural heart disease, electrolyte abnormalities, and concomitant QT-prolonging medications 1.

Risk Assessment Before Fluconazole Use

Key risk factors to identify:

• Female sex (75% of reported cases) 2
• Hypokalemia or hypomagnesemia
• Advanced cardiac failure
• Structural heart disease
• Baseline QT prolongation
• Concomitant QT-prolonging drugs (especially erythromycin, clarithromycin, amiodarone, quinidine) 1
• Renal dysfunction (prolongs fluconazole half-life)

Monitoring Protocol for Fluconazole

The FDA label and guidelines recommend 1, 3:

1. Baseline ECG - Withhold fluconazole if QTc ≥500 ms or known congenital long QT syndrome
2. Follow-up ECG at 7-15 days after initiation or dose changes
3. Monthly monitoring during first 3 months
4. More frequent monitoring if diarrhea develops (increases electrolyte loss)

Stop fluconazole immediately if:

• QTc exceeds 500 ms 3, 4
• ΔQTc increases >60 ms from baseline 3
• TdP occurs

Clinical Evidence

Multiple case reports document fluconazole-induced TdP 2, 5, 6, 7, 8. A 2024 literature review identified 16 cases of azole-induced TdP, with fluconazole accounting for 63% 2. Notably, 75% had concurrent medications, and 81% developed TdP 2. A particularly severe case involved nine cardiac arrests from recurrent TdP in a patient with diabetic ketoacidosis, hypokalaemia, and hypocalcaemia 7.

Common pitfall: The enzyme-inhibiting effect of fluconazole persists 4-5 days after discontinuation due to its long half-life 1. Continue monitoring during this washout period.

Colistin and Torsades de Pointes

Colistin does not directly prolong the QT interval. Instead, it can cause a Bartter-like syndrome through renal tubular dysfunction, leading to severe electrolyte disturbances that secondarily trigger TdP 9.

Colistin-Induced Electrolyte Pattern

The characteristic constellation includes 9:

• Hypokalemia
• Hypocalcemia
• Hypomagnesemia
• Metabolic alkalosis
• Despite normal renal function (distinguishes from acute kidney injury)

Monitoring Protocol for Colistin

1. Baseline electrolytes and ECG before starting colistin
2. Daily electrolyte monitoring during first week
3. Every 2-3 days thereafter while on therapy
4. ECG if electrolyte abnormalities develop or symptoms occur

Critical action: If TdP develops despite aggressive electrolyte repletion, discontinue colistin immediately 9. The arrhythmia is drug-refractory until colistin is withdrawn, as demonstrated in the reported case where repeated defibrillation and electrolyte replacement failed until drug cessation 9.

Combined Use Considerations

When both drugs are necessary:

The combination creates additive risk through different mechanisms - direct QT prolongation (fluconazole) plus electrolyte-mediated QT prolongation (colistin). This scenario demands:

• Continuous telemetry monitoring in ICU setting
• Twice-daily electrolyte checks (potassium >4.5 mEq/L, magnesium >2 mg/dL) 10
• Daily ECG during first week
• Immediate drug review if QTc >500 ms or approaches 500 ms

The 2016 IDSA aspergillosis guidelines note that azoles should be administered with caution to patients with cardiac disorders that increase arrhythmia risk 11. While this refers to azole-azole or azole-other drug combinations, the principle applies to any combination increasing TdP risk.

Management of TdP When It Occurs

Per AHA/ACC guidelines 12, 10:

1. Immediate actions:

   • Discontinue offending agent(s)
   • IV magnesium sulfate 1-2 g (even if serum magnesium normal) 10
   • Replete potassium to 4.5-5.0 mEq/L 10

2. For recurrent TdP:

   • Temporary transvenous pacing (highly effective) 10
   • Isoproterenol infusion (increases heart rate, shortens QT) 10

3. Avoid: Class Ia and III antiarrhythmics (will worsen QT prolongation)

The enzyme-inhibiting effect of fluconazole persists 4-5 days post-discontinuation 1, so arrhythmia risk may continue briefly even after stopping the drug. The colistin-induced electrolyte disturbances, however, are immediately reversible upon drug withdrawal 9.